Nexus (NXU) Q3 2025 earnings summary

Executive summary

• Achieved strong growth in Q3 2025, with revenue up 9.9% year-over-year to €209.7m and EBITDA up 12.4% to €45.9m.

• Successfully shielded operations from sector challenges and ongoing crises, outperforming industry peers.

• Completed three strategic acquisitions, expanding presence in AI-driven healthcare software and women's and infant health.

• Order backlog expanded with major project wins in Germany, France, Austria, and Poland.

Financial highlights

• Revenue rose to €209.7m (up 9.9% year-over-year); domestic sales up 17.9%, international sales stable.

• EBITDA increased 12.4% to €45.9m; EBIT up 15.8% to €31.5m; EBT up 15.2% to €32.3m.

• Net income grew 13.9% to €23.1m; EPS up 15.3% to €1.36.

• Operating cash flow surged 56.1% to €43.3m; liquidity at €126.7m as of September 30, 2025.

• Balance sheet total increased 17.9% to €489.7m; equity ratio at 62.3%.

Outlook and guidance

• Management remains confident in further growth, citing strong project pipeline and market opportunities.

• Focus on optimizing business processes and achieving annual targets despite economic headwinds.